


REMARKS

The foregoing Preliminary Amendment is requested in order to place the claims in conformity with United States patent practice. No statutory new matter has been added. Therefore, the Applicants respectfully request that the amendment be entered.

It is not believed that extensions of time are required, beyond those that may otherwise be provided for in accompanying documents. However, in the event that additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. §1.136(a), and any fees required therefor are hereby authorized to be charged to our Deposit Account No. 210380, referencing Attorney Docket No. 12694/P66821US2 (RIID 99-12).

Respectfully submitted,
JACOBSON HOLMAN, PLLC

Suzannah K. Sundby
Reg. No. 43,172

Date: 24 September 2001
The Jenifer Building
400 Seventh Street, N.W.
Washington, DC 20004-2201
(202) 662-8497

09960315 092401
104260 STE09660

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the specification:

This application is a continuation of U.S. patent application Serial No. 09/523,271, filed on 10 March 2000, entitled Deglycosylated Ricin Toxin A-Chain Vaccine, naming Robert W. Wannemacher and John F. Hewetson as inventors, which claimed the benefit of priority from U.S. provisional patent application Serial No 60/124,283, filed on 12 March 1999. [This application claims the benefit of priority from U.S. Application serial no. 60/124,283 filed March 12, 1999.]

09960315-092401
FOI260-STE09660